Olema Pharmaceuticals: The Market Forgot This Pipeline Doesn't Need a Blockbuster Yet

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Olema Pharmaceuticals typically reports earnings before market open, meaning Day 0 represents the first full trading session where investors react to results, while Day +1 captures follow-through momentum.

OLMA exhibits volatile and unpredictable price behavior around earnings, with an average absolute Day 0 move of 5.37% and Day +1 move of 6.14%. The most recent earnings (May 2026) saw the stock decline 5.99% on Day 0 despite meeting estimates, followed by continued weakness. The prior report (March 2026) triggered a sharp 12.85% rally on Day 0, only to reverse 9.31% lower the following session—illustrating how initial reactions can quickly unwind.

The historical data shows no consistent directional bias, with Day 0 moves ranging from -9.28% to +12.85% across the past eight reports. Notably, the Day +1 moves average 6.14% in absolute terms but show even wider swings, including a +16.19% surge in August 2025 and a -9.90% drop in August 2024. The average Day 0 range of 8.28% and Day +1 range of 12.65% underscore the stock's tendency for intraday whipsaws, making OLMA particularly challenging for short-term traders around earnings events.

Part 2.2: Options Market Expected Move

The options market is currently pricing in a 0.00% expected move for the August 21 expiration, which appears to be a data anomaly given OLMA's historical volatility around earnings. Based on the stock's average absolute Day 0 move of 5.37% and Day +1 move of 6.14%, investors should anticipate a potential swing in the 5-6% range following the August 10 release, despite the absence of a calculated implied move in the options chain.

Part 3: What Analysts Are Saying

Analysts maintain a strongly bullish stance on Olema Pharmaceuticals, with the consensus rating at 4.69 out of 5.0—firmly in Strong Buy territory. The breakdown shows 11 Strong Buy ratings, 0 Moderate Buys, 2 Holds, and no Sell ratings among the 13 analysts covering the stock. This lopsided distribution reflects conviction in OLMA's long-term potential despite near-term losses.

The average price target of $40.70 implies substantial 238% upside from the current price of $12.05, with estimates ranging from a low of $23.00 (91% upside) to a high of $62.00 (415% upside). This wide range suggests divergent views on the probability and timeline of commercial success, though even the most conservative target implies near-doubling potential.

Analyst sentiment has remained unchanged over the past month, with the rating composition and average recommendation of 4.69 holding steady versus one month ago. This stability suggests analysts are maintaining their bullish thesis despite the stock's technical weakness and recent underperformance. The lack of downgrades following the May earnings report—where OLMA met but did not beat estimates—indicates the Street is willing to look past near-term execution challenges and focus on the longer-term value proposition tied to palazestrant's clinical development.

Part 4: Technical Picture

Olema Pharmaceuticals enters earnings with a deteriorating technical picture, as the Barchart Technical Opinion has weakened from a 72% Sell signal both last week and last month to a current 40% Sell reading. While this represents a modest improvement in the very near term, the overall signal remains negative, indicating underlying weakness in the stock's momentum and trend structure.

Timeframe Analysis:

• Short-term (Hold): Neutral signal suggests the immediate trend has stabilized after recent weakness, though lacks conviction for a sustained bounce
• Medium-term (50% Sell): Moderate sell signal indicates the intermediate-term trend remains under pressure with downside risks still present
• Long-term (100% Sell): Strong sell signal reflects significant deterioration in the longer-term trend, with the stock well below key moving averages

Trend Characteristics: The trend is characterized as Weak with Weakest directional momentum, suggesting OLMA lacks the technical foundation for a strong post-earnings rally and remains vulnerable to further downside if results disappoint.

The stock is trading at $12.05, positioned above its 5-day ($11.69), 10-day ($11.66), 20-day ($11.62), and 50-day ($11.34) moving averages, indicating some short-term stabilization. However, OLMA remains below both its 100-day ($13.06) and 200-day ($17.50) moving averages, confirming the longer-term downtrend remains intact. The 100-day average at $13.06 represents immediate overhead resistance, while the 200-day at $17.50 stands as a significant technical hurdle.

The clustering of short-term moving averages just below the current price provides modest support in the $11.34-$11.69 range, but the 31% gap between the current price and the 200-day moving average illustrates the magnitude of technical damage. With average implied volatility at 106.59%, options traders are pricing in significant uncertainty. The overall technical setup is cautionary heading into earnings, as the stock lacks bullish momentum and sits in a vulnerable position where a disappointment could trigger a test of the 50-day moving average, while even a positive surprise may struggle to generate sustained follow-through given the overhead resistance and weak long-term trend characteristics.